A rare heart disease has two kinds of drug racing to treat it. A failed trial just shook the race.

A rare, often fatal heart condition called transthyretin amyloid cardiomyopathy, or ATTR-CM, has two competing kinds of medicine. This summer, one of those medicines, a so-called "silencer," failed a closely watched Phase 3 trial, and some analysts are calling it a verdict on the entire silencer class. The trial was actually asking a different question than the one that matters most for newly diagnosed patients.

ATTR-CM happens when a misfolded protein called transthyretin builds up in the heart muscle, stiffening it until it cannot pump effectively. Most patients are diagnosed after age 60 and survive only a few years without treatment. Two drug classes have been racing to slow that decline. "Stabilizers" were the first, pills that lock the transthyretin protein in place so it cannot misfold. "Silencers" came next, injected RNA-targeted drugs that tell the liver to make less transthyretin in the first place. Alnylam's Amvuttra (vutrisiran) and AstraZeneca and Ionis's Wainua (eplontersen) are both silencers.

On July 9, AstraZeneca reported that Wainua had missed the primary endpoint of its Phase 3 trial, called CARDIO-TTRansform, in patients with ATTR-CM. The company's shares fell roughly 9% on the news. The most damaging read, as STAT reported in late August, was that eplontersen offered no additional benefit when layered on top of tafamidis, a stabilizer, and that in that combination setting the older pill might be the better drug. That interpretation, in the words of one analyst STAT cited, "tanked the whole Phase 3 study."

The company's argument is that CARDIO-TTRansform was the wrong test of silencers. Its own Phase 3 trial, HELIOS-B, was largely a monotherapy study: vutrisiran given to patients who were mostly not on a stabilizer, and it read out positive. As Alnylam put it in a 2024 statement, the data show the "unique, differentiated value of vutrisiran as a first-line treatment option." The HELIOS-B paper, published in the New England Journal of Medicine, concluded that "treatment with vutrisiran led to a lower risk of death from any cause and cardiovascular events than placebo and preserved functional capacity and quality of life."

That distinction is the part most readers never see. HELIOS-B asked whether a silencer helps if you give it to a patient first. CARDIO-TTRansform asked whether adding a silencer helps if a patient is already taking a stabilizer. The two trials are not the same experiment, and a failure in the second does not automatically answer the first.

But the distinction has limits, and Alnylam's defense runs into one. HELIOS-B included a small subgroup of patients already on tafamidis at baseline, and that subgroup did not show the same mortality benefit as the overall population. The "clean monotherapy" framing of HELIOS-B is therefore softer than the company's public messaging suggests. The most the data can say is that vutrisiran has the strongest evidence as a first-line option in patients who are not already on a stabilizer.

The stakes for Alnylam extend beyond Amvuttra. Its next-generation silencer, nucresiran, is in late-stage development, and the CARDIO-TTRansform failure is being read by some investors as a sign for the class. If a stabilizer-first treatment paradigm hardens, silencer developers of every generation will be answering for it. The competitive picture is also tightening: BridgeBio's acoramidis, another stabilizer, reported positive Phase 3 data in ATTR-CM earlier this year, sharpening the stabilizers-versus-silencers contest.

What patients on Amvuttra and the cardiologists prescribing it should take from this is narrower than the headlines suggest. The silencer class has not been judged; one trial in one specific combination has been. The more useful question for the next year is whether nucresiran can reproduce HELIOS-B's monotherapy result in a design closer to that original one, and whether Alnylam will defend the class by running that trial.